Anthos Therapeutics Inc.

Merger-and-acquisition activity in the biopharmaceutical sector had almost nowhere to go but up in the first quarter of 2025, following a historically low quarter in terms of total potential deal valu

Six years after licensing out abelacimab to Anthos Therapeutics, a venture it co-founded with Blackstone Life Sciences, Novartis has brought the drug back into its cardiovascular pipeline. The Swiss g

Regeneron Pharmaceuticals expects to see downward pressure on the 2mg version of Eylea (aflibercept) continue after 2024, but demand for the VEGF inhibitor has remained high despite the introduction o

In a battle with Bristol Myers Squibb/Johnson & Johnson, Bayer and privately held Anthos to bring the first factor XI anticoagulant product to market, Regeneron reported on 19 December that its pa